Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Braun, Jürgen; Blanco, Ricardo; Marzo-Ortega, Helena; Gensler, Lianne S.; van den Bosch, Filip; Hall, Stephen; Kameda, Hideto; Poddubnyy, Denis; van de Sande, Marleen; Wiksten, Anna S.; Porter, Brian O.; Shete, Abhijit; Richards, Hanno B.; Haemmerle, Sibylle; Deodhar, Atul

doi:10.6084/m9.figshare.16570952.v1

13075_2021_2613_MOESM1_ESM.docx (39.36 kB)

Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

journal contribution

posted on 2021-09-05, 03:13 authored by Jürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Abhijit Shete, Hanno B. Richards, Sibylle Haemmerle, Atul Deodhar

Additional file 1: Table S1. Number of patients in each subgroup. Table S2. Key efficacy endpoints by subgroups and by gender at screening analysed at Week 16. Table S3. Additional efficacy endpoints in the subgroups analysed at Week 16.

Funding

novartis pharma ag, basel, switzerland

History

Usage metrics

Keywords

Non-radiographic axial spondyloarthritis C-reactive protein Magnetic resonance imaging Interleukins Biologicals Human leukocyte antigen B27 Gender

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Funding

novartis pharma ag, basel, switzerland

History

Usage metrics

Categories

Keywords

Licence

Exports